HGH 191AA (Somatropin)
HGH · Human Growth Hormone · Somatropin · rhGH · Norditropin · Genotropin · Humatrope · Saizen
HGH 191AA refers to recombinant human growth hormone produced via E. coli or mammalian cell expression with the native 191-amino-acid sequence (somatropin). This is the FDA-approved form sold as Genotropin (Pfizer), Humatrope (Eli Lilly), Norditropin (Novo Nordisk), Saizen (Merck-Serono), Omnitrope (Sandoz), and Zomacton (Ferring), among others. Distinguished from older 192AA preparations (somatrem, with an extra N-terminal methionine) and from 'generic' research-grade HGH that may not match the native sequence.
Starting dose. 1 IU — ~0.33mg
Most users dose at bedtime to mimic endogenous nocturnal GH peak. Reconstitute lyophilized vial with bacteriostatic water - do NOT shake (denatures protein). Inject into thigh or abdominal subcutaneous tissue. Rotate sites. Avoid heavy meals 2 hours pre-dose for full GH/IGF-1 pulse.
Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.
How it works
Somatropin binds the growth hormone receptor (GHR), a class I cytokine receptor expressed broadly on hepatocytes, adipocytes, chondrocytes, immune cells, and many other tissues. GHR ligation triggers JAK2-STAT5 signaling, with downstream transcriptional activation of IGF-1 and IGFBP-3 (primarily in liver) and direct local effects in target tissues.
Linear Growth (children)
GH-driven hepatic IGF-1 stimulates chondrocyte proliferation in growth plates - the basis of GHD pediatric replacement.
Lipolysis
GHR activation in adipocytes increases hormone-sensitive lipase activity and free fatty acid release - drives fat mass loss particularly in visceral depots.
Anabolic Action
GH-driven IGF-1 increases muscle protein synthesis, satellite cell activation, and lean mass. GH itself has direct anti-catabolic action via insulin-like signaling at high concentrations.
Insulin Antagonism
GH antagonizes insulin action at high levels - clinically relevant only at supraphysiologic doses or in GH excess (acromegaly). Therapeutic doses produce mild glucose excursions; supraphysiologic doses can cause overt insulin resistance.
Bone Density
Chronic GH replacement in adult GHD increases BMD modestly via direct osteoblast and indirect IGF-1 effects.
Connective Tissue
GH/IGF-1 stimulates collagen synthesis - basis of off-label injury-recovery use, though human data limited to GHD populations.
What to expect
Week 1-2: water retention, joint stiffness, possible mild edema. IGF-1 begins rising. Subjective sleep changes possible.
Week 4-12: peak body composition response - reduced visceral fat, modest lean mass gain. Improved exercise recovery anecdotally.
Month 3-6 and beyond: sustained body composition with continued daily dosing. Long-term safety in non-FDA-approved populations not established.
Evidence
Claims we could not support
No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.
Dose/route: 1 IU (~0.33mg); Subcutaneous (SubQ) injection; 1x daily (or split AM/PM). No checked live PubMed abstract verified this exact displayed dose, route, and frequency for the same molecule/formulation and relevant population.
Mechanism: Somatropin binds the growth hormone receptor (GHR), a class I cytokine receptor expressed broadly on hepatocytes, adipocytes, chondrocytes, immune cells, and many other tissues. GHR ligation triggers JAK2-STAT5 signaling, with downstream transcriptional activation of IGF-1 and IGFBP-3 (primarily in liver) and direct local effects in target tissues. 1. Linear Growth (children): GH-driven hepatic IGF-1 stimulates chondrocyte proliferation in growth plates - the basis of GHD pediatric replacement. 2. Lipolysis: GHR activation in adipocytes increases hormone-sensitive lipase activity and free fatty acid release - drives fat mass loss particularly in visceral depots. 3. Anabolic Action: GH-driven IGF-1 increases muscle protein synthesis, satellite cell activation, and lean mass. GH itself has direct anti-catabolic action via insulin-like signaling at high concentrations. 4. Insulin Antagonism: GH antagonizes insulin action at high levels - clinically relevant only at supraphysiologic doses or in GH excess (acromegaly). Therapeutic doses produce mild glucose excursions; supraphysiologic doses can cause overt insulin resistance. 5. Bone Density: Chronic GH replacement in adult GHD increases BMD modestly via direct osteoblast and indirect IGF-1 effects. 6. Connective Tissue: GH/IGF-1 stimulates collagen synthesis - basis of off-label injury-recovery use, though human data limited to GHD populations.. No checked live PubMed abstract provided an exact-molecule/formulation sentence supporting this source-JSON mechanism claim.
Primary safety claim: No primary safety text present in source JSON. No checked live PubMed abstract directly verified this source-JSON safety claim at the displayed formulation, route, and regimen.
Side effects & safety
Commonly reported
- Water retention, edema (face, hands, ankles)
- Joint pain and stiffness
- Carpal tunnel syndrome symptoms (wrist tingling)
- Mild hyperglycemia / impaired fasting glucose
- Injection site reaction
- Headache
- Vivid dreams
Less common & notes
- Insulin resistance progressing to overt type 2 diabetes at supraphysiologic doses.
- Acromegaly-like features (jaw growth, brow ridge prominence, hand/foot enlargement) at chronic supraphysiologic exposure.
- Unmasking of subclinical hypothyroidism (GH suppresses T4-to-T3 conversion).
- Theoretical malignancy promotion via IGF-1 mitogenic action - acromegaly epidemiology suggests modestly increased colon cancer risk.
- Rare benign intracranial hypertension (pseudotumor cerebri) - new headache + visual changes warrants immediate workup.
- Slipped capital femoral epiphysis in pediatric patients with predisposing factors.
- Allergic reaction to formulation rare.
- Long-term cardiovascular outcomes in healthy adults using off-label GH not characterized.
Pharmacokinetics
Plasma; IGF-1 effect persists 16-24h
Post-injection (SubQ)
Via IGF-1 downstream
subQ ~75-80%
Daily dosing standard for both replacement and off-label use
Hepatic and renal proteolysis
Storage. Lyophilized vial: refrigerate (2-8°C / 36-46°F). Do NOT freeze - freezing denatures the protein. Light-sensitive. After reconstitution with bacteriostatic water: refrigerate, use within 14-28 days per manufacturer label. Do NOT shake during reconstitution - swirl gently to dissolve. Discard if cloudy, discolored, or contains particulates. Pen devices have specific post-loading expiration windows - check manufacturer instructions.
Regulatory status
FDA-approved as Genotropin (Pfizer), Humatrope (Eli Lilly), Norditropin (Novo Nordisk), Saizen (Merck-Serono), Omnitrope (Sandoz), Zomacton (Ferring), Serostim (HIV wasting). All require prescription. Distribution for non-FDA-approved indications is restricted by 21 USC 333(e) - federal criminal statute making distribution of HGH for non-approved use a felony. Prohibited by WADA in class S2 both in and out of competition. Sale of research-grade HGH for human use is illegal in the United States; the 'research chemical' framing common for other peptides does NOT apply to HGH 191AA which is uniquely federally restricted.
Put it to work
Calculate, log & track
Open HGH 191AA (Somatropin) straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.
Open HGH 191AA (Somatropin) in the app →Go deeper
The guide & community
The complete HGH 191AA (Somatropin) walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.
Join the community ↗